RhumbLine Advisers’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11M | Sell |
44,815
-6,804
| -13% | -$1.48M | 0.01% | 1051 |
|
|
2026
Q1 | $8.72M | Sell |
51,619
-614
| -1% | -$106K | 0.01% | 1124 |
|
|
2025
Q4 | $9.54M | Sell |
52,233
-8,545
| -14% | -$1.19M | 0.01% | 1082 |
|
|
2025
Q3 | $7.38M | Sell |
60,778
-1,029
| -2% | -$116K | 0.01% | 1228 |
|
|
2025
Q2 | $6.45M | Buy |
61,807
+7,047
| +13% | +$746K | 0.01% | 1283 |
|
|
2025
Q1 | $6.39M | Buy |
54,760
+3,515
| +7% | +$400K | 0.01% | 1229 |
|
|
2024
Q4 | $4.34M | Sell |
51,245
-148
| -0.3% | -$13.6K | ﹤0.01% | 1495 |
|
|
2024
Q3 | $4.62M | Sell |
51,393
-3,538
| -6% | -$309K | ﹤0.01% | 1472 |
|
|
2024
Q2 | $4.42M | Buy |
54,931
+2,674
| +5% | +$198K | ﹤0.01% | 1463 |
|
|
2024
Q1 | $4.17M | Buy |
52,257
+1,620
| +3% | +$136K | ﹤0.01% | 1503 |
|
|
2023
Q4 | $4.03M | Sell |
50,637
-208
| -0.4% | -$13.9K | ﹤0.01% | 1550 |
|
|
2023
Q3 | $3.55M | Buy |
50,845
+4,135
| +9% | +$309K | ﹤0.01% | 1536 |
|
|
2023
Q2 | $3.36M | Buy |
46,710
+2,633
| +6% | +$194K | ﹤0.01% | 1619 |
|
|
2023
Q1 | $2.72M | Buy |
44,077
+1,138
| +3% | +$74.8K | ﹤0.01% | 1647 |
|
|
2022
Q4 | $3.31M | Buy |
42,939
+4,083
| +11% | +$244K | ﹤0.01% | 1530 |
|
|
2022
Q3 | $1.73M | Buy |
38,856
+4,372
| +13% | +$218K | ﹤0.01% | 1841 |
|
|
2022
Q2 | $1.32M | Buy |
34,484
+5,063
| +17% | +$160K | ﹤0.01% | 1994 |
|
|
2022
Q1 | $1.22M | Sell |
29,421
-165
| -0.6% | -$5.12K | ﹤0.01% | 2051 |
|
|
2021
Q4 | $1.12M | Sell |
29,586
-344
| -1% | -$12.7K | ﹤0.01% | 2160 |
|
|
2021
Q3 | $986K | Buy |
29,930
+366
| +1% | +$14.3K | ﹤0.01% | 2227 |
|
|
2021
Q2 | $1.99M | Sell |
29,564
-1,168
| -4% | -$70.1K | ﹤0.01% | 1949 |
|
|
2021
Q1 | $1.74M | Sell |
30,732
-4,968
| -14% | -$349K | ﹤0.01% | 1972 |
|
|
2020
Q4 | $2.91M | Buy |
35,700
+1,041
| +3% | +$77.8K | ﹤0.01% | 1656 |
|
|
2020
Q3 | $2.47M | Sell |
34,659
-9,260
| -21% | -$722K | ﹤0.01% | 1557 |
|
|
2020
Q2 | $3.61M | Buy |
43,919
+5,888
| +15% | +$453K | 0.01% | 1393 |
|
|
2020
Q1 | $2.24M | Buy |
38,031
+3,455
| +10% | +$282K | ﹤0.01% | 1488 |
|
|
2019
Q4 | $3.57M | Buy |
34,576
+2,777
| +9% | +$112K | 0.01% | 1462 |
|
|
2019
Q3 | $644K | Buy |
31,799
+525
| +2% | +$13.5K | ﹤0.01% | 2233 |
|
|
2019
Q2 | $805K | Buy |
+31,274
| New | +$627K | ﹤0.01% | 2154 |
|
|
2017
Q2 | – | Sell |
-13,688
| Closed | -$53K | – | 2927 |
|
|
2017
Q1 | $53K | Buy |
+13,688
| New | +$65.4K | ﹤0.01% | 2818 |
|
Other funds holding AXSM
DTC
RhumbLine Advisers's AXSM Position: Q2 2026 in Review
RhumbLine Advisers reduced its Axsome Therapeutics (AXSM) stake by 13% in Q2 2026, selling an estimated $1.48M and leaving 44,815 shares worth $11M. The position accounts for 0.01% of the portfolio, ranked #1051.
RhumbLine Advisers first reported a position in AXSM in Q1 2017 and has held it in 30 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.
- RhumbLine Advisers held 44,815 shares of Axsome Therapeutics worth $11M as of Q2 2026.
- RhumbLine Advisers sold 6,804 Axsome Therapeutics shares in Q2 2026, an estimated $1.48M.
- Axsome Therapeutics made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1051 holding.
- RhumbLine Advisers first reported a position in Axsome Therapeutics in Q1 2017 and has held it in 30 quarters since.
- 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.